```html

Janus Kinase (JAK) Inhibitor–Related Infection

Overview

Janus kinase (JAK) inhibitors are a class of oral or injectable medications that block the activity of one or more of the JAK enzymes (JAK1, JAK2, JAK3, and TYK2). By interfering with the JAK‑STAT signaling pathway, these drugs reduce inflammation and are approved for a growing list of autoimmune and inflammatory conditions, such as rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, atopic dermatitis, and certain myeloproliferative neoplasms.

Because the JAK‑STAT pathway is also essential for normal immune surveillance, inhibiting it can increase susceptibility to infections. The term JAK inhibitor–related infection refers to any bacterial, viral, fungal, or opportunistic infection that occurs (or worsens) while a patient is taking a JAK inhibitor.

• Who it affects: Adults and, increasingly, adolescents receiving JAK inhibitors for chronic inflammatory diseases. The risk is higher in patients with additional immunosuppressive therapy (e.g., corticosteroids, methotrexate).
• Prevalence: In clinical trials, serious infections occurred in 2–4 % of patients on tofacitinib, baricitinib, or upadacitinib, compared with 1–2 % on placebo or non‑JAK DMARDs. Real‑world registries report similar rates, with higher numbers in older adults (>65 y) and those with comorbid lung disease (CDC, 2023).

Symptoms

Infections can involve any organ system. Below is a comprehensive list of common and less common presentations, grouped by system. Remember that symptoms may be subtle early on because the immune response is blunted.

General (systemic) signs

• Fever or low‑grade temperature (often <38 °C in JAK‑treated patients)
• Chills or rigors
• Unexplained fatigue or malaise
• Unintended weight loss

Respiratory

• Cough (dry or productive)
• Sore throat or hoarseness
• Shortness of breath, wheezing, or chest tightness
• Pain on deep breathing (pleuritic chest pain)
• Runny or congested nose (rhinorrhea)

Gastrointestinal

• Nausea, vomiting, or loss of appetite
• Diarrhea (watery or bloody)
• Abdominal cramping or pain
• Rectal bleeding or melena

Genitourinary

• Urinary frequency, urgency, or burning
• Cloudy, foul‑smelling, or bloody urine
• Painful genital lesions or discharge

Skin & Soft Tissue

• Red, warm, painful area (cellulitis)
• Abscess formation or draining sores
• Herpes‑zoster (shingles) rash – often more severe
• Petechiae or purpura (possible sign of viral infection or thrombocytopenia)

Neurologic

• Headache, confusion, or altered mental status
• Neck stiffness (meningitis)
• Focal weakness or sensory loss (possible CNS infection)

Other notable infections

• Reactivation of latent tuberculosis (TB)
• Opportunistic fungal infections (e.g., Pneumocystis jirovecii pneumonia, candidiasis)
• Viral reactivations (herpes simplex, cytomegalovirus, hepatitis B)

Causes and Risk Factors

JAK inhibitors reduce the signaling of cytokines such as interleukins 6, 12, 23, and interferons, which are critical for mounting an effective immune response. When this pathway is dampened, the body’s ability to recognize and eliminate invading organisms declines.

Primary causes

• Pharmacologic effect: Direct inhibition of JAK enzymes → impaired leukocyte activation, reduced antibody production, and diminished interferon‑mediated antiviral defenses.
• Drug‑specific potency: Tofacitinib (JAK1/3), baricitinib (JAK1/2), upadacitinib (JAK1‑selective) each have slightly different infection profiles based on selectivity and dose.

Risk factors that magnify infection risk

• Age ≥ 65 years
• Concurrent use of systemic corticosteroids (≥10 mg prednisone equivalent daily) or other biologics
• Pre‑existing chronic lung disease (COPD, interstitial lung disease)
• Diabetes mellitus or uncontrolled hyperglycemia
• History of recurrent infections or prior opportunistic infection
• Active or latent tuberculosis, hepatitis B/C, or HIV
• Smoking, alcohol misuse, or malnutrition
• High disease activity (e.g., severe rheumatoid arthritis) that itself predisposes to infection

Diagnosis

Because the clinical picture may be muted, a high index of suspicion is essential. Diagnosis combines a thorough history, physical examination, and targeted investigations.

Step‑by‑step approach

1. History: Document duration and progression of symptoms, recent travel, exposure to sick contacts, vaccination status, and any prior infections.
2. Medication review: Verify dose, duration, and any recent changes in JAK inhibitor therapy or concurrent immunosuppressants.
3. Physical exam: Look for focal signs (e.g., skin lesions, lymphadenopathy, lung crackles) and assess vital signs.
4. Laboratory tests:
   • Complete blood count (CBC) with differential – leukopenia or neutropenia can signal severe infection.
   • Comprehensive metabolic panel (CMP) – assess kidney and liver function before initiating antimicrobials.
   • Inflammatory markers: C‑reactive protein (CRP) and erythrocyte sedimentation rate (ESR) – often modestly elevated.
   • Specific pathogen testing based on presentation:
     • Blood cultures (2 sets) for fever >38 °C.
     • Sputum Gram stain and culture for respiratory symptoms.
     • Urine dipstick and culture for dysuria.
     • Stool PCR or culture for watery/bloody diarrhea.
     • HIV, hepatitis B/C serologies if risk factors present.
5. Imaging:
   • Chest X‑ray – first line for cough, dyspnea, or fever.
   • CT chest/abdomen/pelvis if X‑ray unclear or suspicion of deep‑seated infection.
   • Joint ultrasound or MRI for suspected septic arthritis.
6. Special tests for opportunistic pathogens:
   • Quantiferon‑TB Gold or T‑Spot.TB before starting therapy; re‑screen if symptoms arise.
   • Serum (1→3)-β‑D‑glucan or galactomannan for invasive fungal infection.
   • PCR for herpesviruses, CMV, or EBV when viral reactivation is suspected.

Treatment Options

Treatment balances controlling the infection while maintaining control of the underlying disease.

Immediate steps

• **Temporarily hold** the JAK inhibitor until the infection is adequately treated (most guidelines recommend pausing for moderate‑to‑severe infections).
• Begin empiric antimicrobial therapy based on the most likely source and local resistance patterns, then tailor once cultures return.

Antimicrobial regimens (examples)

• Upper respiratory infections: Amoxicillin‑clavulanate 875/125 mg PO BID for 7–10 days, or azithromycin 500 mg PO daily ×3 days if atypical pathogens are suspected.
• Community‑acquired pneumonia: Levofloxacin 750 mg PO daily ×5 days or ceftriaxone 1 g IV daily + azithromycin 500 mg PO daily.
• Urinary tract infection: Nitrofurantoin 100 mg PO BID ×5 days (if no renal impairment) or trimethoprim‑sulfamethoxazole 160/800 mg PO BID ×3 days.
• Skin/soft‑tissue infection: Clindamycin 600 mg PO TID ×7 days or TMP‑SMX if MRSA risk.
• Herpes‑zoster: Valacyclovir 1 g PO TID ×7 days; consider oral steroids only if severe pain and no contraindications.
• Opportunistic fungal infection: Initiate oral fluconazole 200 mg PO daily for candida; for Pneumocystis jirovecii pneumonia, high‑dose TMP‑SMX plus adjunctive steroids.
• TB reactivation: Standard 4‑drug regimen (isoniazid, rifampin, pyrazinamide, ethambutol) for 2 months, followed by continuation phase—JAK inhibitor usually held for the intensive phase.

Adjunctive measures

• Hydration and antipyretics (acetaminophen) for fever.
• Analgesics for pain control that do not further depress immunity (avoid high‑dose NSAIDs if renal risk).
• Consider prophylactic antibiotics (e.g., TMP‑SMX) in patients with prior opportunistic infections or prolonged high‑dose steroids.

Resuming JAK inhibitor therapy

After clinical resolution and a minimum of 48 hours of infection‑free status, discuss with your rheumatologist or gastroenterologist:

• Whether to restart the same dose or switch to a lower‑dose formulation.
• If a different class of therapy (e.g., IL‑6 inhibitor) may be safer given infection history.

Living with Janus Kinase (JAK) Inhibitor–Related Infection

Managing life on a JAK inhibitor is feasible with a few practical habits.

Daily management tips

• Medication log: Keep a notebook or app entry noting the start date, dose, and any missed doses.
• Vaccinations: Stay up‑to‑date with inactivated vaccines (influenza, pneumococcal, COVID‑19). Live vaccines (e.g., varicella, Zostavax) are generally contraindicated while on therapy; discuss timing with your provider.
• Hand hygiene: Wash hands for at least 20 seconds before meals and after contact with public surfaces.
• Skin care: Use gentle moisturizers, avoid harsh soaps, and inspect skin daily for cuts or rashes.
• Oral health: Brush twice daily, floss, and schedule dental check‑ups every six months; oral infections can seed systemic disease.
• Monitor vitals: A simple daily temperature check can catch low‑grade fevers early.
• Nutrition & sleep: Aim for a balanced diet rich in protein, fruits, vegetables, and at least 7 hours of sleep to support immune function.
• Travel precautions: Verify travel vaccinations, carry a standby antibiotic kit (as advised by your physician), and avoid consuming raw or undercooked foods in high‑risk regions.

When to contact your healthcare team

• Fever ≥38 °C that lasts >24 hours.
• New or worsening cough, shortness of breath, or chest pain.
• Severe sore throat with difficulty swallowing.
• Persistent diarrhea (>3 days) or blood in stool.
• Unusual skin lesions, especially vesicular rash or rapidly spreading redness.
• Sudden joint swelling, redness, or inability to bear weight.

Prevention

Prevention hinges on risk‑assessment, vaccination, and lifestyle measures.

• Baseline screening before initiation: Tuberculosis (IGRA), hepatitis B surface antigen & core antibody, HIV test, and CBC.
• Vaccination schedule:
  • Influenza — annually (inactivated).
  • Pneumococcal — PCV20 or PCV13 followed by PPSV23 per CDC guidelines.
  • COVID‑19 — up‑to‑date booster series.
  • Shingles — recombinant zoster vaccine (Shingrix) is safe and preferred.
• Prophylactic antimicrobial therapy: For patients with previous opportunistic infection or prolonged high‑dose steroids, prophylaxis with TMP‑SMX 1 tablet daily may be prescribed (NIH, 2022).
• Regular monitoring: Lab work (CBC, LFTs, renal) every 3–6 months, plus more frequent checks if you develop symptoms.
• Healthy habits: No smoking, limit alcohol, maintain a healthy weight, and control diabetes or other chronic illnesses.

Complications

If an infection is not recognized or treated promptly, serious complications can arise:

• Sepsis and septic shock: Life‑threatening organ dysfunction; mortality rises to 30 % in immunocompromised patients.
• Chronic organ damage: Untreated pneumonia may lead to bronchiectasis; intra‑abdominal sepsis can cause adhesions or bowel strictures.
• Opportunistic infection dissemination: For example, disseminated cryptococcosis affecting the CNS.
• Reactivation of latent TB or hepatitis B: Can evolve into active disease with hepatic failure or pulmonary cavitation.
• Increased disease flares: Infection‐driven inflammation may exacerbate the underlying autoimmune condition.

When to Seek Emergency Care

---

**Sources:** Mayo Clinic. “JAK inhibitors: Uses, side effects, and more.” 2023; Centers for Disease Control and Prevention (CDC). “Guidelines for prevention and treatment of opportunistic infections in immunocompromised adults.” 2023; National Institutes of Health (NIH). “Management of immunosuppressed patients.” 2022; American College of Rheumatology (ACR) 2024 guideline on the use of JAK inhibitors; World Health Organization (WHO). “Tuberculosis and Hepatitis B screening recommendations.” 2022; Cleveland Clinic. “Infection risk with biologic and targeted synthetic DMARDs.” 2024.

```